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Abstract
Aims Survival beneﬁt of percutaneous mitral valve repair with the MitraClip over conservative treatment of functional mitral
regurgitation (MR) remains unclear. The purpose of this meta-analysis is to compare survival outcomes of MitraClip with those
of medical therapy in patients with functional MR.
Methods and results A comprehensive literature search of PubMed, MEDLINE, and Google Scholar was conducted including
studies evaluating MitraClip vs. medical therapy with multivariate adjustment and with >80% of patients with functional MR.
Death from any cause was the primary endpoint, while freedom from readmission was the secondary one, evaluated with ran-
dom effects. These analyses were performed at study level and at patient level including only functional MR when available,
evaluating the effect of MitraClip in different subgroups according to age, ischaemic aetiology, presence of implantable
cardioverter deﬁbrillator/cardiac resynchronization therapy, and left ventricular ejection fraction and volumes. We identiﬁed
six eligible observational studies including 2121 participants who were treated with MitraClip (n = 833) or conservative ther-
apy (n = 1288). Clinical follow-up was documented at a median of 400 days. At study-level analysis, MitraClip, when compared
with medical therapy (P = 0.005), was associated with signiﬁcant reduction of death (P = 0.002) and of readmission due to
cardiac disease. At patient-level analysis, including 344 patients, MitraClip conﬁrmed robust survival beneﬁt over medical ther-
apy for all patients with functional MR and among the most important subgroups.
Conclusions Compared with conservative treatment, MitraClip is associated with a signiﬁcant survival beneﬁt. Importantly,
this superiority is particularly pronounced among patients with functional MR and across all the main subgroups.
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Introduction
Functional mitral regurgitation (MR) is a frequent complica-
tion in heart failure patients owing to left ventricular remod-
elling processes causing papillary muscle dislocation and
leaﬂet tethering, and it is associated with an adverse progno-
sis.1,2 Surgical correction for functional MR is controversial
with no consistent outcomes for patients in terms of survival
and quality of life and reports of suboptimal outcomes and
signiﬁcant perioperative mortality.3,4 In addition, a large
number of patients with functional MR are not referred for
surgery, and many other patients are rejected for open-heart
surgery because of a predicted high surgical risk or co-
morbidities.5 Thus, when surgical risk is prohibitive, percuta-
neous mitral valve repair (PMVR) using the MitraClip system
can be considered a valid option for patients with functional
MR who remain symptomatic despite optimal medical ther-
apy.6 Recently, several studies have conﬁrmed that MitraClip
procedure is safe with sustained improvement of haemody-
namic and functional status even in patients with advanced
heart failure, but its impact on survival has not been
established.7–11 To date, there are few non-randomized
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studies that globally report better survival outcome of PMVR
than of conservative treatment in patients with left ventricu-
lar dysfunction and functional MR.12–17
Therefore, we performed a meta-analysis of observational
studies selecting all-cause mortality as primary outcome, in
order to compare PMVR with MitraClip system combined
with medical therapy to medical therapy alone for treatment
of severe functional mitral regurgitation.
Methods
Search methods and resources
The present research was elaborated according to current
guidelines, including the recent Preferred Reporting Items
for Systematic Reviews and Meta-Analyses amendment to
the Quality of Reporting of Meta-analyses statement and
recommendations from The Cochrane Collaboration and
Meta-analysis of Observational Studies in Epidemiology.18–20
Pertinent articles were searched in PubMed, Cochrane, and
Google Scholar for the following terms: ‘mitral regurgitation’
and ‘MitraClip’ and ‘medical therapy’. Two reviewers (C. G.
and F. D. A.) independently reviewed all papers, with dis-
agreements resolved by consensus. Inclusion criteria were
(i) human studies, (ii) studies comparing MitraClip vs. medical
therapy, (iii) follow-up longer than 1 year, (iv) at least 80% of
the patients with functional MR, and (v) studies with multi-
variate adjustment. In the case of duplicate reporting, the
manuscript with the largest sample of patients was selected.
Data abstraction
The following data were independently abstracted by two un-
blinded reviewers (C. G. and F. D. A.) on pre-speciﬁed elec-
tronic forms: authors, journal, year of publication, location
of the study group, baseline, and procedural features. The
corresponding authors of the relevant studies were queried
for required quantitative details not in the published manu-
scripts. When available, only data for patients with functional
MR were included.
Endpoints
All-cause death was the primary endpoint, while re-
hospitalization for cardiac cause was the secondary one.
At patient level, subgroup analysis stratiﬁed according to
age, presence of implantable cardioverter deﬁbrillator/
cardiac resynchronization therapy, cardiomyopathy aetiology,
left ventricular ejection fraction, and volumes was also
performed.
Quality study evaluation
The quality of included studies was independently appraised
by two reviewers (C. G. and F. D. A.), with disagreements re-
solved by consensus. Design of the study (multicentre or not),
area of enrolment, and kinds of multivariate analysis were
collected.
Statistical analysis
Continuous variables are reported as mean (standard devia-
tion) or median (ﬁrst and third quartiles). Categorical
variables are expressed as n (%). Statistical pooling for
incidence estimates was performed according to a random-
effects model with generic inverse-variance weighting, com-
puting risk estimates with 95% conﬁdence intervals (CIs),
using RevMan 5.2 (The Cochrane Collaboration, The Nordic
Cochrane Centre, Copenhagen, Denmark). Hypothesis testing
for superiority was set at the two-tailed 0.05 level. Hypothe-
sis testing for statistical homogeneity was set at the two-
tailed 0.10 level and based on the Cochran Q test, with I2
values of 25%, 50%, and 75% representing mild, moderate,
and severe heterogeneity, respectively.
Results
Study selection
The ﬂow chart is shown in Figure 1. The electronic search
yielded 351 citations that were initially evaluated for eligibil-
ity in title and abstract levels. Once duplicate and irrelevant
publications had been removed, six reports were evaluated
in full text for eligibility and were ﬁnally used in the current
meta-analysis.12–17 Individual patient data for patient-level
meta-analysis were collected from three of the included
studies.12,14,17
Quality of evidence
No randomized controlled trials comparing MitraClip vs.
medical therapy alone were identiﬁed. Of the six studies
included in the meta-analysis, four performed prospective
enrolment at least in one of the two arms and two included
multicentre registries. All studies appraised were from
specialized tertiary referral centres. Only one report was
published as an abstract.17 With the exception of two stud-
ies,16,17 the other studies included >50 patients in each
group of treatment. Four studies exclusively enrolled pa-
tients with functional MR14,15,17 while the remaining studies
included both functional and degenerative MR.12,13,16 From
the study of Swans et al., only outcome data for functional
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MR were included. 15 Otherwise, all patients collected for
patient-level meta-analysis were affected by functional MR.
All but one report12 used a propensity score matching in or-
der to minimize imbalance in key baseline characteristics be-
tween the MitraClip and medical therapy alone groups. All
studies explicitly stated a priori inclusion criteria.
Demographics characteristics
Baseline characteristics of overall population and according
to the included different studies are summarized in Tables 1
and 2, respectively. Overall, 2121 participants who were
treated with MitraClip (n = 833) or conservative therapy
(n = 1288) were included. Patients enrolled were predomi-
nantly male (78%) and characterized by advance age (median
age 71 years), high estimated surgical risk (median logistic
EuroSCORE 21% and median Society of Thoracic Surgeons
score 11%) and a high burden of co-morbidities (i.e. chronic
kidney disease 45%, chronic obstructive pulmonary disease
45%, diabetes mellitus 45%, a history of previous myocardial
infarction 25%, and percutaneous coronary intervention
49%). Despite optimal medical therapy, all patients were
symptomatic for dyspnoea, with 95% in New York Heart Asso-
ciation Class III–IV. The mechanism of MR was functional in
93% of patients with 67% of ischaemic aetiology. With the ex-
ception of one report, the patients’ baseline characteristics
were well matched between the two treatment groups in
all studies.12
Figure 1 Preferred reporting items for systematic reviews and meta-analyses chart.
Table 1 Baseline clinical proﬁle of included patients (for study
level, all data are reported as continuous or percentages with me-
dian and ﬁrst and third inter-quartiles; for patient level, as median
or percentages)
Characteristics
Study-level
cohort
(n = 2121)
Patient-level
cohort
(n = 344)
Age, years 71 (65–82) 74 (67–80)
Male gender 78 (72–81) 81 (67–88)
Body mass index, kg/m2 23 (22–29) 25 (23–27)
Logistic EuroSCORE, % 21 (18–23) 22 (20–24)
STS score, % 11 (8–12) 12 (9–13)
Previous smoker 28 (23–45) 33
Hypertension 36 (32–45) 40
Hyperlipidaemia 37 (32–43) 33
Diabetes mellitus 45 (43–56) 39
Atrial ﬁbrillation 45 (43–65) 49
Chronic obstructive pulmonary
disease
45 (43–90) 72
Chronic kidney disease 45 (43–64) 50
Dialysis 9 (2–7) 8
Coronary artery disease 67 (64–71) 71 (69–81)
Previous myocardial infarction 25 (24–38) 29
Previous percutaneous coronary
intervention
49 (43–54) 54
Ischaemic heart disease 67 (64–81) 70 (68–74)
Functional mitral regurgitation 93 (91–97) 100
History of acute pulmonary
oedema
17 (12–20) 13
NYHA Class III–IV 95 (90–97) 91 (89–96)
ICD/CRT — 74
ICD — 88
CRT, cardiac resynchronization therapy; ICD, implantable
cardioverter deﬁbrillator; NYHA, New York Heart Association; STS,
Society of Thoracic Surgeons: predicted risk of operative mortality.
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In order to compare the effect of MitraClip with that of
medical therapy among patients with functional MR only,
we performed a meta-analysis using individual participant
data. Data from 344 patients with functional MR were col-
lected for individual patient data analysis and matched after
propensity score: 172 (50%) were treated with MitraClip
and 172 (50%) conservatively. All reported baseline clinical
characteristics of the individual patient-level data cohort
were similar to those of the overall cohort (Table 1). Baseline
echocardiographic parameters are detailed in Table 3. The
overall study population showed a severely impaired left ven-
tricular systolic function with a median ejection fraction of
24% (23–36%). Individual patient data meta-analysis further
conﬁrmed left ventricular systolic dysfunction with severely
dilated left ventricle and atrial chambers and increased sys-
tolic pulmonary artery pressure (Table 3).
MitraClip procedure and in-hospital outcome
Procedural results and in-hospital adverse events are deﬁned
in Table 4. Overall procedural time, deﬁned as the time from
trans-septal access with the guide catheter to guide removal
from the vein, was 140 min. There was no procedural mortal-
ity or clip embolization. Profuse bleeding that required multi-
ple transfusions were 13% (9–20%), whereas the incidence of
new onset of atrial ﬁbrillation occurred in 1% (0.5–4%). Ac-
cording to individual patient data, acute procedural success
rate was 93%, with only two patients in whom it was not pos-
sible to implant a clip. In 61% of cases, a single clip was
implanted; in 36% two clips; and in 3% three clips. Stroke,
pericardial tamponade, myocardial infarction, and urgent car-
diovascular surgery for adverse events were not observed.
Vascular complication occurred in 20% while the incidence
of acute renal failure was very low (1%). Pre-discharge echo-
cardiography showed a residual MR > 2 grade in 12% of
patients.
Ta
b
le
2
Ba
se
lin
e
cl
in
ic
al
pr
oﬁ
le
of
en
ro
lle
d
pa
ti
en
ts
ac
co
rd
in
g
to
di
ff
er
en
t
st
ud
ie
s
in
cl
ud
ed
in
th
e
m
et
a-
an
al
ys
is
St
ud
y
N
um
be
r
of
pa
ti
en
ts
Fu
nc
ti
on
al
M
R
A
ge
(y
ea
rs
)
M
al
e
ge
nd
er
ST
S
sc
or
e
(%
)
Lo
gi
st
ic
sc
or
e
(%
)
C
hr
on
ic
ki
dn
ey
di
se
as
e
C
or
on
ar
y
ar
te
ry
di
se
as
e
C
hr
on
ic
ob
st
ru
ct
iv
e
pu
lm
on
ar
y
di
se
as
e
A
tr
ia
l
ﬁ
br
ill
at
io
n
N
YH
A
C
la
ss
III
–
IV
LV
ej
ec
ti
on
fr
ac
ti
on
(%
)
PM
V
R
M
T
PM
V
R
M
T
PM
V
R
M
T
PM
V
R
M
T
PM
V
R
M
T
PM
V
R
M
T
PM
V
R
M
T
PM
V
R
M
T
PM
V
R
M
T
PM
V
R
M
T
PM
V
R
M
T
PM
V
R
M
T
Sw
aa
ns
et
al
.1
2
13
9
59
92
93
76
±
10
73
±
10
68
54
13
.5
±
9
4.
34
±
4
23
.9
±
16
18
.7
±
13
.2
40
31
51
76
22
32
52
41
88
86
37
±
15
34
±
17
V
el
áz
qu
ez
et
al
.1
3
35
1
95
3
70
93
76
±
11
69
±
13
61
49
11
.3
±
7.
7
9.
7
±
8.
8
—
—
31
19
51
43
11
7
69
52
85
47
48
±
14
37
±
11
A
da
m
o
et
al
.1
7
33
33
10
0
10
0
71
±
9
71
±
12
70
67
—
—
—
—
61
58
42
36
24
27
48
55
10
0
10
0
30
±
9
30
±
8
G
ia
nn
in
ie
t
al
.1
4
60
60
10
0
10
0
75
±
8
76
±
8
70
63
4.
9
±
4.
2
3.
8
±
2.
6
21
.1
±
14
20
.9
±
12
.6
48
33
43
28
25
20
35
43
73
75
37
±
15
35
±
11
A
rm
en
ie
t
al
.1
5
23
2
15
1
10
0
10
0
71
±
10
71
±
11
73
74
—
—
—
—
—
—
64
54
25
21
33
33
—
—
34
±
13
32
±
10
A
sg
ar
et
al
.1
6
50
42
10
0
10
0
75
±
9
68
±
16
74
77
—
—
—
—
—
—
78
71
—
—
58
64
98
21
38
±
16
32
±
14
V
al
ue
s
ar
e
m
ea
n
±
SD
or
%
.
LV
,l
ef
t
ve
nt
ri
cl
e;
M
R,
m
it
ra
lr
eg
ur
gi
ta
ti
on
;M
T,
m
ed
ic
al
th
er
ap
y;
N
YH
A
,N
ew
Yo
rk
H
ea
rt
A
ss
oc
ia
ti
on
;P
M
V
R,
pe
rc
ut
an
eo
us
m
it
ra
lv
al
ve
re
pa
ir
w
it
h
M
it
ra
C
lip
.
Table 3 Baseline echocardiographic proﬁle (for study level, all data
are reported as continuous or percentages with median and ﬁrst
and third inter-quartiles; for patient level, as median or
percentages)
Parameters
Study-level
cohort
(n = 2121)
Patient-level
cohort
(n = 344)
LV end-diastolic volume, mL — 187 (148–224)
LV end-diastolic volume > 200 ml — 20
LV ejection fraction, % 24 (23–36) 30 (25–38)
LV ejection fraction < 25% — 33
LA area, cm2 — 30 (25–35)
SPAP, mmHg — 47 (40–55)
SPAP > 60 mmHg — 30
LA, left atrium; LV, left ventricle; SPAP, systolic pulmonary artery
pressure.
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Survival outcomes
Clinical follow-up was documented at a median of 400 days
(376 to 480). There was a total of 133 all-cause mortality:
52 (30%) in the PMVR arm and 81 (47%) in the conservative
group (P < 0.001). The summary estimate comparing PMVR
using MitraClip System combined with medical therapy and
medical therapy alone showed a statistically signiﬁcant rela-
tive risk reduction of death from any cause in favour of PMVR
with homogeneity across reports [odds ratio (OR) 0.79, 95%
CI: 0.68–0.92, P = 0.002; I2 = 96%; τ2 = 0.03] (Figure 2A).
Through the follow-up period, heart failure re-hospitalization
data were reported in three studies: 26 (48%) patients in the
PMVR arm and 47 (60%) patients in the conservative group
(P = 0.02). Overall, a signiﬁcant difference in survival free
from readmission due to cardiac disease favouring MitraClip
over medical therapy alone was observed with homogeneity
across reports (OR 0.73, 95% CI: 0.59–0.91, P = 0.005;
I2 = 89%; τ2 = 0.03) (Figure 2(B)).
Subgroup analysis
Subgroup analysis was available only for individual patient
data (344 participants with functional MR). After a median
follow-up of 304 days (172 to 725), there was evidence of
survival beneﬁt for MitraClip in patients with functional
MR and among all the main subgroups (Figure 3A). The ef-
fect in favour of MitraClip was also conﬁrmed for the sec-
ondary outcome of re-hospitalization across all subgroups
except for patients with ischaemic aetiology and those with
both left ventricle end-diastolic volume < 200 and >200 mL
(Figure 3B).
Table 4 Procedural results and in-hospital outcomes in MitraClip
patients (for study level, all data are reported as continuous or per-
centages with median and ﬁrst and third inter-quartiles; for patient
level, as median or percentages)
Characteristics
Study-level
cohort
(n = 2121)
Patient-level
cohort
(n = 344)
Number of clip
1 — 61
2 — 36
3 — 3
Procedural mortality 0 0
Procedural time, min 140 (118–180) 140 (118–180)
Pericardial tamponade — 0
Urgent cardiovascular surgery — 0
Vascular complication — 21
Bleeding requiring transfusion 13 (9–20) 7
Stroke — 0
New onset of atrial ﬁbrillation 1 (0.5–4) 2
Acute renal failure 1
Myocardial infarction — 0
Clip embolization 0 0
MR grade at discharge
1+/2+ 80 (78–82) 88 (87–91)
3+ 19 (18–23) 12 (8–13)
4+ 1 (0–1) 0
MR, mitral regurgitation.
Figure 2 Random-effects meta-analysis of percutaneous mitral valve repair vs. conservative therapy for study-level analysis. Forest plot showing the
result of meta-analysis of percutaneous mitral valve repair vs. conservative therapy for the primary outcome of death from any causes (A) and for the
secondary outcome of re-hospitalization (B) after a median follow-up of 400 days (376 to 480). The estimate of the odds ratio (OR) of each study cor-
responds to the middle of the squares, and the horizontal line shows the 95% conﬁdence interval (CI). For each subgroup, the sum of the statistics,
along with the summary OR, is represented by the middle of the solid diamonds. A test of heterogeneity between the trials within a subgroup is given
below the summary statistics. OMT, optimal medical therapy; IV, instrumental variable estimation; SE, standard error.
1154 C. Giannini et al.
ESC Heart Failure 2018; 5: 1150–1158
DOI: 10.1002/ehf2.12339
Discussion
The current meta-analysis represents an attempt to assess
the outcomes of PMVR vs. conservative therapy in patients
with heart failure and severe MR.
The main novel ﬁndings of this meta-analysis are summa-
rized as follows:
(a) Compared with medical therapy alone, PMVR with
MitraClip resulted in a signiﬁcant relative risk reduction
of death from any cause in high-risk patients with pre-
dominantly functional MR and advanced heart failure.
(b) Mortality beneﬁts with PMVR over medical therapy were
conﬁrmed in patients who only had functional MR and
were consistent across all the main subgroups.
(c) An overall marked reduction in hospital readmission
for cardiovascular disease favouring MitraClip was also
observed.
(d) The effect in favour of MitraClip for re-hospitalization
was also consistent in patients with functional MR only
and among all subgroups except for patients with ischae-
mic aetiology and those with both left ventricle end-
diastolic volume < 200 and >200 mL.
Functional MR is associated with a poor prognosis in heart
failure patients with post-ischaemic or idiopathic dilated
cardiomyopathy.1 The presence of even mild degrees of func-
tional MR identiﬁes patients with left ventricular dysfunction
who have a higher mortality risk than those without MR.2
The appropriateness of mitral valve surgery for patients with
functional MR remains embroiled in controversy, because
functional MR is the consequence and not the cause of left
ventricular dysfunction.6,21 Moreover, surgical mitral valve re-
pair for functional MR is associated with not negligible periop-
erative mortality, and the number of patients with severe
functional MR who are not referred for surgery because of
high surgical risk, advanced age, and co-morbidities is
increasing.4,5 The introduction of PMVR with the MitraClip de-
vice opened new perspectives for the treatment of patients
with severe MR at very high surgical risk.7 Although less effec-
tive than surgery in reducing MR, the MitraClip showed fewer
perioperative adverse events and achieved a similar durable
improvement in functional MR.9,22 A number of studies have
compared the outcomes of MitraClip with those of surgical re-
pair reporting similar survival rates.12,23,24 However, these
ﬁndings should be interpreted with caution, because of higher
risk proﬁles (higher age, lower ejection fraction, and higher
predicted mortality) in theMitraClip group than in the surgical
repair one. In particular, MitraClip implantation has been
shown as an effective adjunctive therapy for patients with ad-
vanced heart failure and severe functional MR, offering the
chance to obtain a relevant reverse cardiac remodelling and
signiﬁcant improvement in functional class even in highly
symptomatic patients with severely dilated hearts.7,25
What remains unknown is whether the PMVR with
MitraClip device improves survival in patients with moderate
to severe left ventricular failure causing functional MR. Up to
now, there are few non-randomized studies that globally re-
port better survival outcome of PMVR compared with opti-
mal medical therapy in patients with severe MR.12,13,15,16
However, most of these studies include a wide spectrum of
high-risk patients with both functional and degenerative
MR. Recently, we evaluated clinical outcome of patients with
functional MR and reduced left ventricular function treated
conservatively compared with those who received MitraClip
device.14 After propensity analysis, we proved that transcath-
eter mitral valve repair was superior over conservative treat-
ment. Overall survival rates were 89.7%, 61.4%, and 71.2% at
1, 2, and 3 years in the PMVR groups vs. 64.3%, 51.7%, and
34.9% at 1, 2, and 3 years in the conservative group, respec-
tively (P = 0.007).
Therefore, we performed the current meta-analysis of
existing studies to conﬁrm these ﬁndings. Six observational re-
ports and >2121 participants with predominantly functional
Figure 3 Subgroup analyses from individual patient-level data for the primary outcome of death from any causes (A) and for the secondary outcome of
re-hospitalization (B) after a median follow-up of 304 days (172 to 725). Odds ratio (OR) and corresponding conﬁdence intervals for patients subgroups
were pooled, and interactions were evaluated by random-effects meta-analyses. The vertical dashed line on plot represents the point estimate of
OR = 1. Asterisk indicates no signiﬁcant difference. ICD, implantable cardioverter deﬁbrillator; CRT, cardiac resynchronization therapy; EF, ejection frac-
tion; LVED, left ventricle end-diastolic.
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MR (93%) and high surgical risk were included. Our results
highlight the worse outcomes of medically managed patients
affected by severe MR and the better survival beneﬁt of those
treated with endovascular repair (P = 0.03). Furthermore, we
performed a meta-analysis using individual participant data to
clarify the effect of MitraClip vs. medical therapy in patients
with only functional MR. Patient-level analysis conﬁrmed that
MitraClip therapy is superior to conservative treatment even
in patients with functional MR and advanced heart failure
and across all the main subgroups.
In particular, in the cohort of patients with functional MR,
mortality beneﬁt with PMVR over medical therapy is inde-
pendent of age, ischaemic aetiology, presence of implantable
cardioverter deﬁbrillator/cardiac resynchronization therapy,
and left ventricular ejection fraction and volumes. These ﬁnd-
ing are in contrast with those of a previous study that re-
ported an increased risk of all-cause death after MitraClip in
patients presenting an ischaemic aetiology or those with se-
verely dilated left ventricle.26 However, this study presents
several limitations because it included a wide spectrum of
high-risk patients with both functional and degenerative
MR. Recently, the results from Transcatheter Valve Treat-
ment Sentinel Pilot Registry, including 452 patients with func-
tional MR who underwent MitraClip procedure in 25 centres
across Europe, conﬁrmed our results, reporting no signiﬁcant
differences between the two aetiologies (ischaemic or non-
ischaemic) regarding survival at 1 year follow-up.27
However, patients with advanced heart failure still have a
poor prognosis despite MitraClip implantation. This could
be related to advanced stage of evolution of their disease
and may inspire researchers to analyse clinical predictors of
futility of the MitraClip because of the relevant clinical and
economic issues.23,28,29 Recent evidences have identiﬁed se-
vere right ventricular failure as an independent predictor of
cardiovascular mortality in patients with functional MR and
advanced heart failure undergoing MitraClip treatment.28,29
Finally, we reported that patients treated with PMVR expe-
rienced a lower incidence of readmission due to cardiac dis-
ease than did patients treated conservatively (P = 0.03).
These results are comparable with the data from Lim et al.
showing a decrease in re-hospitalization in prohibitive-surgi-
cal-risk patients after MitraClip implantation.30 Transcatheter
reduction of MR in these patients translated to signiﬁcant
beneﬁts, including improvements in symptoms and func-
tional status, favourable left ventricle remodelling, and con-
sequently a decrease in hospitalizations.
Interestingly, we proved that the effect in favour of
MitraClip for the secondary outcome of re-hospitalization
was robust across all subgroups except for patients with isch-
aemic aetiology. Our results are consistent with the data re-
ported by Capodanno et al. showing a signiﬁcant worsening
in terms of re-hospitalization in patients presenting with an
ischaemic aetiology at 2 years’ follow-up.26 These ﬁndings
suggest that an ischaemic setting potentially represents a
more challenging scenario for percutaneous treatment of
MR, stressing the importance of patient selection.
However, to investigate whether PMVR has superior sur-
vival beneﬁt over conservative therapy in high-surgical-risk
patients with functional MR, we need results from random-
ized clinical trials. The ongoing COAPT (Clinical Outcomes As-
sessment of the MitraClip Percutaneous Therapy for High
Surgical Risk Patients) and MITRA FR (Multicentre Study of
Percutaneous Mitral Valve Repair MiraClip Device in Patients
with Severe Secondary Mitral Regurgitation) studies will pro-
vide important additional evidence.
Conclusions
The late outcome of MitraClip compared with medical ther-
apy alone is crucial as the number of MitraClip continues to
increase over the last few years. The current meta-analysis
shows that MitraClip is a safe therapeutic option for selected
high-surgical-risk patients with severe functional mitral regur-
gitation and entails better survival outcomes than do conser-
vative treatment. The hypothesis that transcatheter mitral
valve repair has superior survival beneﬁts vs. conservative
therapy in high-surgical-risk patients with left ventricular dys-
function and functional MR needs to be tested with random-
ized clinical trials, and results from the ongoing clinical trials
(COAPT and MITRA FR) will be helpful in this setting.
Study limitations
The present study has many limitations. First of all, no ran-
domized trials were included in the meta-analysis but only
observational studies owing to the lack of publications
comparing PMVR with conservative treatment. Second,
meta-regression analysis results should be read as hypothesis
generating only, which need to be conﬁrmed in larger studies.
Third, one study included patients from a non-published re-
port but simply from abstract.17 Finally, clinical heterogeneity
may derive from different selections of population in each
centre: Actually, this innovative technique is reserved to pa-
tients at different stages of heart failure. In all but one re-
port,12 a propensity score matching was used to minimize
imbalance in key baseline characteristics between the
MitraClip and medical therapy groups.
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